Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Johannes Hauser, managing director of the German-Mexican Chamber of Commerce explains the role of the chamber in Mexico and encourages small and medium-sized companies in Germany to consider the country…
Oscar Parra, general manager at Lundbeck Mexico, explains the seriousness of CNS diseases in increasingly urbanized countries and the impact they can have on the productivity of the Mexican workforce.…
The first woman appointed as general director of one of the leading neurosciences institutions in Latin America discusses the Institute’s priorities in terms of R&D for brain diseases, training of…
Probiomed wants to move to the next level. The recently appointed general director discusses her plans to grow the business and expand internationally, leveraging the company’s in-house developed biotech products…
Genomic medicine is gaining momentum. The general director of the institute founded in 2004 explains how genomics is helping unlocking the secret codes, which will help understand and treat pathologies…
For 40 years Apotex has made providing patients around the globe with access to quality and affordable medicines its priority. The general director for Northern Latin America discusses the importance…
Rodrigo Iturralde, general manager of Randall, walks us through the new plans of the company after a year of difficult yet enriching challenges and the ambitious goals set with an…
Healthcare coverage has gone a long way in Mexico after the implementation of the Seguro Popular in 2004 and today 57.3 million Mexicans are affiliated to the public health insurance…
In 2014 the National Academy of Medicine celebrated its 150th anniversary. The president of the renowned medical institution discusses the recent activities of the academy, the importance of increasing transparency…
The president of the Health Commission at the Senate and former vice minister for integration and development for the 2006-2011 administration talks about the importance of ensuring high-quality healthcare services…
The general manager of the leading information solutions provider for the pharmaceutical and healthcare industry talks about the challenges Mexican patients face in the public sector, how large pharmacy chains…
Eugenio Garcia Verde, general manager at Glenmark Mexico, reveals the company’s ambitious aim to see the brand amongst the top 40 in Mexico and top 20 worldwide by 2020. …
See our Cookie Privacy Policy Here